CTLA4 and neoplasm: Furthermore, a combination of anti-CTLA-4 and anti-PD-1 antibodies with the pan-HDACI belinostat potentiated the efficacy of these antibodies via upgrading the immune function and reducing tumor volume in a murine hepatocellular carcinoma model [176].